5 noteworthy pharma AI investments in 2023

The last year showed how some of the world’s biggest pharma companies are leveraging AI tech.

By Alexandra Pecci • Dec. 19, 2023

Babson gets one step closer to delivering on Theranos-like blood testing

A recent FDA clearance could pave the way to pin-prick blood tests at local pharmacies and potentially one day, clinical trials.

By Kelly Bilodeau • Dec. 18, 2023

Explore the Trendline➔

Oncology

As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

By PharmaVoice staff

Rise of the chief investment officer: Why the unique role works for Roivant

Dr. Mayukh Sukhatme, president and chief investment officer for Roivant, discusses the long game of partnering and business deals in biopharma.

By Alexandra Pecci • Dec. 18, 2023

The many ‘myths’ of clinical trial diversity, and Genentech’s fight to disrupt them

Genentech’s chief diversity officer Quita Highsmith is on a crusade to prove that much of what the industry believes about clinical trial diversity is wrong.

By Michael Gibney • Dec. 14, 2023

A former CDC head on key R&D areas, public trust and if we learned anything from COVID-19

Dr. Julie Gerberding, now president and CEO of the Foundation for the National Institutes of Health, shares lessons learned from a long career in academic, public health and industry.

By Meagan Parrish • Dec. 13, 2023

What’s being done to prepare for the next pandemic?

Will the world be ready when a new outbreak hits? Here’s a look at the efforts to combat emerging viral threats.

By Kelly Bilodeau • Dec. 13, 2023

Patients who hide pills and advocacy offices that could get ‘raided’ — a Gilead leader on navigating global HIV

Gilead Sciences’ SVP of global patient solutions discusses how she’s managing some of the world’s most complicated health issues and what’s next in HIV innovation.

By Alexandra Pecci • Dec. 11, 2023

Discovering the next frontier of blood cancer care

How AstraZeneca is expanding its haematology footprint through the advancement of cutting-edge science in blood cancers.

Dec. 11, 2023

The FDA just approved the first CRISPR drug. Here’s what’s next in gene editing.

A look at the fast-evolving pipeline for gene editing therapies.

By Meagan Parrish • Dec. 8, 2023

Real Chemistry’s CEO on biopharma’s outlook in 2024

Shankar Narayanan, CEO of marketing consulting firm Real Chemistry, weighs in on where the industry is headed in the New Year.

By Michael Gibney • Dec. 7, 2023

CRISPR eyes autoimmune disease in revamp of cell therapy plans

The gene editing biotech is shelving two of its most advanced cancer drugs, and joining a growing group of companies exploring cell-based medicines for inflammatory diseases like lupus.

By Ben Fidler • Dec. 6, 2023

The weight loss market looks unstoppable. How high could it go?

Market expectations for obesity drugs are soaring and competition is heating up. But hitting the heights will require overcoming payer and other issues.

By Kelly Bilodeau • Dec. 4, 2023

Octave Bioscience is navigating the Parkinson’s labyrinth with Michael J. Fox’s help

A grant from the notorious Parkinson’s foundation has sped up Octave’s timeline to further advance biomarker development in the field.

By Kelly Bilodeau • Nov. 29, 2023

Biopharma’s top 5 IPOs of 2023 (so far)

Despite one major outlier, 2023’s IPOs haven’t hit the heights of the past three years.

By Alexandra Pecci • Nov. 28, 2023

The head of AstraZeneca’s new digital health business on how the pharma is leveraging tech

Cristina Durán, formerly AstraZeneca’s chief digital officer of R&D and now head of digital health business Evinova, believes data will help pharma screen and treat patients earlier in their disease.

By Michael Gibney • Nov. 28, 2023

How EMD Serono plans to hit its lofty goals in R&D

The company’s global heads of oncology R&D reveal how strategic partnerships are key to its launch plans following layoffs in the U.S.

By Alexandra Pecci • Nov. 27, 2023

As alcohol-related deaths climb, new drugs could curb the urge to drink

A drug developed by Kinnov Therapeutics halved alcohol consumption in heavy drinkers in a mid-stage study.

By Kelly Bilodeau • Nov. 27, 2023

Organon’s chief medical officer wants to change how the world sees women’s health

Dr. Juan Camilo Arjona Ferreira joined Organon in September and says the company is “like a lighthouse in women’s health” in its visibility and focus.

By Michael Gibney • Nov. 22, 2023

The biopharma COO’s playbook

Connie Chang, COO at ONL Therapeutics, describes what it takes to bring a CEO’s vision to life.

By Alexandra Pecci • Nov. 21, 2023

Biohaven wants to muscle in on the Ozempic craze with a competing class of drugs

Biohaven and other companies are aiming to develop meds with a different mechanism of action that trim the waistline while building lean tissue.

By Kelly Bilodeau • Nov. 20, 2023

​​A startling drop in U.S. life expectancy — and how pharma could help turn the tide

The recently observed dip was particularly acute for men, who now live an average of 5.8 fewer years than women.

By Meagan Parrish • Nov. 17, 2023

AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?

Dr. Paul Moss, a hematology expert in the U.K., conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19.

By Michael Gibney • Nov. 16, 2023

A biotech tackles drug discovery with transcription factor know-how

Talus Bio, which developed a platform to map transcription factors, has a lead cancer candidate in the works and consults with other industry players in the complicated biology.

By Michael Gibney • Nov. 15, 2023

The power of genomics-based healthcare remains largely untapped

23andMe co-founder and CEO Anne Wojcicki discusses ways the industry could integrate genomics into healthcare.

By Alexandra Pecci • Nov. 15, 2023

6 ways to improve clinical trial diversity — as shown by J&J

Johnson & Johnson Innovative Medicine’s director of diversity, equity and inclusion in clinical trials shares key strategies for making DEI work.

By Alexandra Pecci • Nov. 14, 2023